Summary The effective management of advanced colorectal cancer has traditionally been viewed in terms of treatment outcome measures such as efficacy (survival, objective response and palliation) and safety. Although these outcomes are of paramount importance and are essential for the evaluation of the effectiveness and tolerability of treatment, they do not take account of the global effect of therapy on patients, society and healthcare systems. Furthermore, they may not reveal important differences between treatments of equivalent antitumour efficacy that might influence the overall effectiveness in terms of acceptability of therapy. To achieve this, a broader, patient-centred evaluation of advanced cancer treatment is required that acknowledges the views, experience and perspectives of all involved in the treatment process. To this end, the International Working Group in Colorectal Cancer, a multidisciplinary group that encompasses expertise from a range of relevant fields and disciplines, has advocated a multidisciplinary approach to the treatment of advanced colorectal cancer that is likely to deliver the best possible overall care.
The three major types of therapy in colorectal cancer (CRC) are surgery, chemotherapy and radiation therapy, each of which is applied differently depending on whether the aim of treatment is curative or palliative (i.e. to control symptoms and extend survival). For example, when used in the curative setting, the purpose of surgery is to excise completely the tumour; chemotherapy is used to eradicate micrometastatic disease and radiation therapy is used to enhance local control of the tumour. In the palliative setting, the tumour may be partly excised to relieve obstruction, chemotherapy is used to achieve an objective response or to stabilize the disease and radiotherapy can help to provide pain relief and to delay symptomatic progression. Palliative therapy in advanced gastrointestinal cancer may offer benefits to patients in terms of improved or maintained performance status, weight gain and reductions in disease-related symptoms, and may extend survival compared with best supportive care (Nordic Gastrointestinal Tumor Adjuvant Therapy Group, 1992; Pyrhonen et al, 1992 ; Rougier et al, 1992; Scheithauer et al, 1993; Palmer et al, 1994; Glimelius et al, 1995) . The assessment of quality of life presents a challenge in cancer care, and there are many factors to be considered, including disease progression, toxicity, inconvenience of some chemotherapy treatment regimens and loss of body function and image associated with a permanent colostomy.
For the purposes of this discussion, advanced CRC is defined as colorectal cancer that at presentation or recurrence is either metastatic or so locally advanced that surgical resection is unlikely to be carried out with curative intent. Although there are a number of end points that may be considered in advanced CRC, the effective management of this disease has been viewed traditionally in terms of cure and survival, with the additional end points of objective response rate, local control and palliation. These classic outcome measures have been used to assess treatment success in many studies published to date. The value of these end points to the effective management of advanced CRC is indisputable, and they are an integral part of the assessment of treatment outcome. However, a greater appreciation is now being shown of other treatment end points including stabilization of disease, improvements in quality of life, patient satisfaction and convenience of treatments for patients, and the overall cost-effectiveness or cost benefits associated with therapy. In the past, these outcomes were often considered to be secondary end points, but they are increasingly being considered by clinicians and other healthcare providers to be of equal importance to standard treatment outcomes, such as disease control, survival and objective response (Donovan et al, 1989; Moinpour et al, 1989 ; Redmond, 1997) .
The broader approach to the evaluation of the treatment of advanced CRC, which takes into account the perspectives of all involved and focuses on the patient's needs and preferences, has been addressed in recent years by the work of the International Working Group in Colorectal Cancer (IWGCRC). This is a multidisciplinary group that includes representatives from medical, radiation and surgical oncology, and from nursing and pharmacy. The objectives of this international working group are to investigate current perceptions of the management of advanced CRC in France, Germany, Italy, the UK and the USA, and to develop international recommendations for the multidisciplinary management of advanced CRC.
DESIGNING THERAPIES TO ENHANCE PATIENT-CENTRED OUTCOMES
Patients see and exchange information with different members of the healthcare team at different times, and all members of the team 'Tomudex' is a trademark, the property of Zeneca. Results expressed as percentages of patients who were evaluable at each dosage level are shown above each bar (Minsky et al, 1992a) need to monitor the results of treatment and respond appropriately. The need for more effective liaison between different clinical disciplines is illustrated by the observation that preoperative radiation therapy or combined modality therapy in patients with rectal cancer who undergo surgery may be associated with a more favourable outcome (reduced toxicity and better preservation of sphincter function) than post-operative therapy (Minsky et al, 1992ci; Rouanet et al, 1995; Hyams et al] 1997; Maghfoor et al, 1997 ). An example of how patient-centred end-points such as reduced incidence of acute side-effects and the avoidance of permanent colostomy might be used to improve the overall effectiveness of treatment is shown by the following data from the Memorial Sloan-Kettering Cancer Center (Minsky et al, 1992a) . Post-operative radiation plus systemic chemotherapy is the most effective adjuvant therapy after surgery for transmural and/or node-positive resectable rectal cancer (Gastrointestinal Tumor Study Group, 1985; Douglass et al, 1986; Krook et al, 1992) . However, it is also associated with a 25-50% incidence of grade 3+ toxicity. Some advantages of preoperative therapy have been noted, including increased resectability and increased chance of sphincter-sparing surgery. A retrospective comparison of two parallel phase I clinical studies was performed to compare preoperative and post-operative adjuvant treatment. In one trial (Minsky et al, 1991) , 16 patients with unresectable rectal cancer received two cycles of bolus 5-fluorouracil (5-FU) (200-250 mg m-' with leucovorin 200 mg m-2) plus radiation (total dose of 5040 cGy to the pelvis) before surgery, followed by a median two further cycles of chemotherapy after surgery. In the second trial (Minsky et al. 1992b ), 25 patients with resectable disease were given the same regimen, but with all treatments being administered after surgery.
Despite significantly more patients in the preoperative group than in the post-operative group having received the higher dosage (250 mg m-2) of 5-FU (75% vs 32%, P = 0.02), the overall incidence of acute grade 3+ toxicity was significantly higher in postoperative than in preoperative patients (Figure 1 ). The two grade 3 toxicities in the preoperative patient group were gastrointestinal in nature, whereas there were seven gastrointestinal and two genitourinary toxicity reports, and four grade 4 toxicities, in the postoperative group. The data illustrate how the overall effectiveness of a treatment may be augmented to the patient's benefit through the design of a regimen that minimizes toxicity relative to other treatment schedules. They also demonstrate the importance of tolerability as an end point worthy of primary consideration by all those involved with the care of the patient.
A further example of how treatment can be manipulated to preserve the patient's quality of life is to be found in several series of data from non-randomized clinical studies in which therapies (Williams, 1984; Rouanet et al, 1993) . The traditional rationale for this procedure lies in the natural history of these tumours, with their high risk of local recurrence (Domergue et al, 1988) , the need for a 2-cm distal margin (Pollett and Nicholls, 1983; Williams et al, 1983) (Wagman et al, 1997) and 'perfect' in 71% (Rouanet et al, 1995) of evaluable patients. Although the phase I/II data that suggest that preoperative therapy has lower acute toxicity and enhances sphincter preservation need to be confirmed in a randomized trial, the results are nonetheless illustrative of qualityof-life end points.
PATIENT CONSIDERATIONS AND SOCIAL, SOCIETAL AND COMMUNITY PERSPECTIVES
The global effect of treatment on the patient is of significant importance and consists of several overlapping aspects, including physical distress (e.g. adverse effects of treatment) and psychological stress (e.g. anxiety, depression and problems associated with body image) (Redmond, 1997 (Bonsel et al, 1993) .
Patients also experience the damaging psychological effects of loss of body image when faced with the possibility of loss of sphincter function in rectal cancer and the prospect of stoma care.
There are also social, societal and community-related perspectives to consider in anti-cancer therapy. These issues tend to be neglected by physicians and include the stresses on the patient as described earlier. Families and close friends may experience the negative aspects of cancer treatment, which include financial factors, social isolation and stress, in a similar way to the patient.
These are all issues relevant to the discussion of quality-of-life end points and the overall implications of treatment of advanced CRC.
Anti-cancer treatments also have a major impact on medical and nursing workloads: two regimens might be similar in efficacy but might differ in their adverse effect profiles and complexity and frequency of delivery. Effective communication across medical, surgical and paramedical disciplines and with patients is needed to identify treatments that are more convenient to deliver and manage.
A PATIENT.CENTRED MULTIDISCIPLINARY MANAGEMENT MODEL Using the patient-centred multidisciplinary management model, the patient is considered as being at the centre of a continual process (patient-centred) that starts at diagnosis and ends, for all patients with advanced disease, in death. Components that feed into this therapeutic process are shown in Figure 3 . General practitioners and patient support services are pictured against the patient to show their continuing presence and input from beginning to end. Other practitioners, including medical and radiation oncologists, surgeons and oncology nurses sometimes have contact with the patient for only relatively short and discrete periods after diagnosis, and there is therefore a tendency to neglect the need for continual and ongoing care and support. Ideally, all disciplines should operate together as a single unit, with the patient at the centre of the treatment process at all times.
This process benefits both patients and care providers, with the interprofessional exchange of information being of particular value to physicians who prescribe treatment. The economic, social and societal impact of each treatment should also be assessed. The multidisciplinary approach to the management of patients with advanced CRC addresses important treatment end points that tend to be overlooked, although they are, according to the patientcentred model, as important as survival. These include tolerability, quality of life and patient satisfaction. Thus, in the assessment of British Journal of Cancer (1998) 77(Supplement 2), 1-4 0 Cancer Research Campaign 1998 therapy for advanced CRC, patient satisfaction with treatment is a goal. There is a wide range of outcomes to be considered, and accurate quality-of-life information (if available) makes a major contribution to improving the management of these patients (Donovan et al, 1989) . The IWGCRC has recommended the adoption of the multidisciplinary approach to deliver the best overall evaluations and subsequent outcomes for patients. Furthermore, it has identified the need for and the composition of the multidisciplinary team, has put forward international treatment recommendations and is currently discussing the development of tools to assist with the assessment of patient satisfaction.
